Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%

Benzinga

2024-12-04

2025 Guidance

Sales	$5.6 - $6.0 billion (8% - 10% constant currency growth)
TAVR	$4.1 - $4.4 billion (5% - 7% constant currency growth)
TMTT	$500 - $530 million (50% - 60% constant currency growth)
Surgical	$970 million - $1.05 billion (mid-single digit constant currency growth)
FX Impact on Sales	~$100 million unfavorable (~2pt downside to reported growth)
Adjusted Gross Profit Margin	78% - 79%
Adjusted Operating Margin	27% - 28%
Tax Rate	15% - 18%
Adjusted EPS	$2.40 - $2.50
Diluted Shares Outstanding	585 – 595 million

Increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth
- Mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS
- TMTT increasing contribution to growth, reaching $2 billion by 2030
- Increasing contribution from new therapeutic areas including Structural Heart Failure and AR

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2488166231"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488166231\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2488166231?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-04 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488166231","market":"us","top_or_hot":-1,"title":"Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%","media":"Benzinga","content":"<html><body><p><strong>2025 Guidance</strong></p><figure><table><tbody><tr><td colspan=\"1\" rowspan=\"1\">Sales</td><td colspan=\"1\" rowspan=\"1\"><p>$5.6 - $6.0 billion</p><p><i>(8% - 10% constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">TAVR</td><td colspan=\"1\" rowspan=\"1\"><p>$4.1 - $4.4 billion</p><p><i>(5% - 7% constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">TMTT</td><td colspan=\"1\" rowspan=\"1\"><p>$500 - $530 million</p><p><i>(50% - 60% constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">Surgical</td><td colspan=\"1\" rowspan=\"1\"><p>$970 million - $1.05 billion</p><p><i>(mid-single digit constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">FX Impact on Sales</td><td colspan=\"1\" rowspan=\"1\"><p>~$100 million unfavorable</p><p><i>(~2pt downside to reported growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted Gross Profit Margin</td><td colspan=\"1\" rowspan=\"1\">78% - 79%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted Operating Margin</td><td colspan=\"1\" rowspan=\"1\">27% - 28%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Tax Rate</td><td colspan=\"1\" rowspan=\"1\">15% - 18%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted EPS</td><td colspan=\"1\" rowspan=\"1\">$2.40 - $2.50</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Diluted Shares Outstanding</td><td colspan=\"1\" rowspan=\"1\">585 – 595 million</td></tr></tbody></table></figure><ul><li>Increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth<ul><li>Mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS</li><li>TMTT increasing contribution to growth, reaching $2 billion by 2030</li><li>Increasing contribution from new therapeutic areas including Structural Heart Failure and AR</li></ul></li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2024-12-04 19:07</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><strong>2025 Guidance</strong></p><figure><table><tbody><tr><td colspan=\"1\" rowspan=\"1\">Sales</td><td colspan=\"1\" rowspan=\"1\"><p>$5.6 - $6.0 billion</p><p><i>(8% - 10% constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">TAVR</td><td colspan=\"1\" rowspan=\"1\"><p>$4.1 - $4.4 billion</p><p><i>(5% - 7% constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">TMTT</td><td colspan=\"1\" rowspan=\"1\"><p>$500 - $530 million</p><p><i>(50% - 60% constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">Surgical</td><td colspan=\"1\" rowspan=\"1\"><p>$970 million - $1.05 billion</p><p><i>(mid-single digit constant currency growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">FX Impact on Sales</td><td colspan=\"1\" rowspan=\"1\"><p>~$100 million unfavorable</p><p><i>(~2pt downside to reported growth)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted Gross Profit Margin</td><td colspan=\"1\" rowspan=\"1\">78% - 79%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted Operating Margin</td><td colspan=\"1\" rowspan=\"1\">27% - 28%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Tax Rate</td><td colspan=\"1\" rowspan=\"1\">15% - 18%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted EPS</td><td colspan=\"1\" rowspan=\"1\">$2.40 - $2.50</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Diluted Shares Outstanding</td><td colspan=\"1\" rowspan=\"1\">585 – 595 million</td></tr></tbody></table></figure><ul><li>Increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth<ul><li>Mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS</li><li>TMTT increasing contribution to growth, reaching $2 billion by 2030</li><li>Increasing contribution from new therapeutic areas including Structural Heart Failure and AR</li></ul></li></ul>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"愛德華茲","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/24/12/42310332/edwards-lifesciences-expects-2025-sales-of-5-6b-6b-vs-consensus-of-5-91b-with-adjusted-eps-of-2-40-","article_id":"2488166231","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488166231","pubTimestamp":1733310435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"2025 GuidanceSales$5.6 - $6.0 billion(8% - 10% constant currency growth)TAVR$4.1 - $4.4 billion(5% - 7% constant currency growth)TMTT$500 - $530 million(50% - 60% constant currency growth)Surgical$970 million - $1.05","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"Edwards Lifesciences预计2025年销售额为$5.6 B-$6B，而市场预期为$5.91 B，调整后每股收益为$2.40-$2.50，而市场预期为$2.44，重申2024年固定汇率销售增长指引为8%-10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"2025 GuidanceSales$5.6 - $6.0 billion(8% - 10% constant currency growth)TAVR$4.1 - $4.4 billion(5% - 7% constant currency growth)TMTT$500 - $530 million(50% - 60% constant currency growth)Surgical$970 million - $1.05 billion(mid-single digit constant currency growth)FX Impact on Sales~$100 million unfavorable(~2pt downside to reported growth)Adjusted Gross Profit Margin78% - 79%Adjusted Operating Margin27% - 28%Tax Rate15% - 18%Adjusted EPS$2.40 - $2.50Diluted Shares Outstanding585 – 595 millionIncreasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growthMid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESSTMTT increasing contribution to growth, reaching $2 billion by 2030Increasing contribution from new therapeutic areas including Structural Heart Failure and AR","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1}}}